# SLC27A4 Antibody / Solute carrier family 27 member 4 [clone 30S71] (FY13230)

| Catalog No. | Formulation | Size |
|---|---|---|
| FY13230 | Rabbit IgG in phosphate buffered saline, pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol, 0.4-0.5mg/ml BSA | 100 ul |

Recombinant RABBIT MONOCLONAL

**Bulk quote request**

| | |
|---|---|
| **Availability** | 2-3 weeks |
| **Species Reactivity** | Human |
| **Format** | Liquid |
| **Clonality** | Recombinant Rabbit Monoclonal |
| **Isotype** | Rabbit IgG |
| **Clone Name** | 30S71 |
| **Purity** | Affinity-chromatography |
| **Buffer** | Rabbit IgG in phosphate buffered saline, pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol, 0.4-0.5mg/ml BSA. |
| **UniProt** | Q6P1M0 |
| **Applications** | Western Blot : 1:500-1:2000<br>Immunohistochemistry : 1:50-1:200<br>Immunocytochemistry/Immunofluorescence : 1:50-1:200<br>Immunoprecipitation : 1:50 |
| **Limitations** | This SLC27A4 antibody is available for research use only. |

## Description

SLC27A4 antibody detects Solute carrier family 27 member 4, encoded by the SLC27A4 gene. Solute carrier family 27 member 4, also called FATP4, is a fatty acid transport protein that plays a central role in uptake and activation of long chain and very long chain fatty acids. SLC27A4 antibody provides researchers with a critical tool to study lipid metabolism, skin barrier function, and metabolic disorders.

Solute carrier family 27 member 4 catalyzes the import of fatty acids across membranes and activates them to acyl-CoA derivatives for use in metabolism. Research using SLC27A4 antibody has shown that it is expressed at high levels in skin keratinocytes and intestinal epithelia, where it contributes to lipid absorption and barrier formation. By coupling transport with enzymatic activation, SLC27A4 ensures efficient utilization of fatty acids in biosynthetic and energy producing

pathways.

Mutations in SLC27A4 cause ichthyosis prematurity syndrome, a rare autosomal recessive skin disorder characterized by premature birth, respiratory complications, and defective skin barrier formation. Studies with SLC27A4 antibody have revealed that loss of function disrupts epidermal lipid organization, resulting in impaired barrier integrity. These findings highlight the essential role of SLC27A4 in skin and epithelial health.

Beyond genetic disease, altered expression of SLC27A4 has been linked to obesity, diabetes, and cancer. Research using SLC27A4 antibody has demonstrated that changes in fatty acid uptake and activation can influence metabolic homeostasis, contributing to insulin resistance and tumor growth. Because lipid metabolism is a key determinant of cellular energy status and membrane synthesis, SLC27A4 serves as a potential therapeutic target.

SLC27A4 antibody is widely applied in western blotting, immunohistochemistry, and immunofluorescence. Western blotting confirms protein expression across tissues, immunohistochemistry highlights localization in skin and intestine, and immunofluorescence reveals membrane distribution. These applications make SLC27A4 antibody valuable for studying lipid biology and metabolic disease.

By providing validated SLC27A4 antibody reagents, NSJ Bioreagents supports research into fatty acid metabolism, skin biology, and systemic disease. Detection of Solute carrier family 27 member 4 allows researchers to explore how lipid uptake and activation contribute to development and pathology.

## Application Notes

Optimal dilution of the SLC27A4 antibody should be determined by the researcher.

## Immunogen

A synthesized peptide derived from human SLC27A4 was used as the immunogen for the SLC27A4 antibody.

## Storage

Store the SLC27A4 antibody at -20oC.